Header Logo

Connection

NAGESHWARA V. DASARI to Neuroectodermal Tumors, Primitive

Back to Details
This is a "connection" page, showing publications NAGESHWARA V. DASARI has written about Neuroectodermal Tumors, Primitive.
NAGESHWARA V. DASARI
Connection Strength
0.818
Neuroectodermal Tumors, Primitive
  1. A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors. Invest New Drugs. 2023 Jun; 41(3):421-430.
    View in: PubMed
    Score: 0.818
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.